Constitutively nuclear FOXO3a localization predicts poor survival and promotes Akt phosphorylation in breast cancer

PLoS ONE

Volumn 5, Issue 8, 2010, Pages

  Chen, Jie ^a,b   Gomes, Ana R ^b   Monteiro, Lara J ^b   Wong, San Yu ^a   Wu, Lai Han ^a   Ng, Ting Ting ^b   Karadedou, Christina T ^b   Millour, Julie ^b   Ip, Ying Chi ^a   Cheung, Yuen Nei ^a   Sunters, Andrew ^b,c   Chan, Kelvin Y K ^a   Lam, Eric W F ^b   Khoo, Ui Soon ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c ROYAL VETERINARY COLLEGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SHORT HAIRPIN RNA; TAMOXIFEN; TRANSCRIPTION FACTOR FKHRL1; FORKHEAD TRANSCRIPTION FACTOR; FOXO3 PROTEIN, HUMAN;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INVASION; CANCER SURVIVAL; CELL CULTURE; CELL CYCLE ARREST; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRADUCTAL CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; NUCLEAR LOCALIZATION SIGNAL; PREDICTION; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; TISSUE MICROARRAY; UPREGULATION; WESTERN BLOTTING; ACTIVE TRANSPORT; BREAST TUMOR; CELL NUCLEUS; DRUG EFFECT; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PAGET NIPPLE DISEASE; PATHOLOGY; PHOSPHORYLATION; SURVIVAL; TUMOR CELL LINE;

ACTIVE TRANSPORT, CELL NUCLEUS; BREAST NEOPLASMS; CARCINOMA, DUCTAL; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHATIC METASTASIS; NEOPLASM INVASIVENESS; PHOSPHORYLATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT; SURVIVAL ANALYSIS; TAMOXIFEN;

EID: 77957924629     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0012293     Document Type: Article

References (33)

1. Ali S, Coombes RC (2002) Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2: 101-112.
2. Elkak AE, Mokbel K (2001) Pure antiestrogens and breast cancer. Curr Med Res Opin 17: 282-289.
3. Yamashita H (2008) Current research topics in endocrine therapy for breast cancer. Int J Clin Oncol 13: 380-383.
4. Goss PE, Muss HB, Ingle JN, Whelan TJ, Wu M (2008) Extended adjuvant endocrine therapy in breast cancer: current status and future directions. Clin Breast Cancer 8: 411-417.
5. Johnston SR (1997) Acquired tamoxifen resistance in human breast cancer- potential mechanisms and clinical implications. Anticancer Drugs 8: 911-930.
6. Clarke R, Skaar TC, Bouker KB, Davis N, Lee YR, et al. (2001) Molecular and pharmacological aspects of antiestrogen resistance. J Steroid Biochem Mol Biol 76: 71-84.
7. Clarke R, Leonessa F, Welch JN, Skaar TC (2001) Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacol Rev 53: 25-71.
8. Duffy MJ (2005) Predictive markers in breast and other cancers: a review. Clin Chem 51: 494-503.
9. Freedman OC, Verma S, Clemons MJ (2005) Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution? Cancer Treat Rev 31: 1-17.
10. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, et al. (2001) Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem 276: 9817-9824.
11. Faridi J, Wang L, Endemann G, Roth RA (2003) Expression of constitutively active Akt-3 in MCF-7 breast cancer cells reverses the estrogen and tamoxifen responsivity of these cells in vivo. Clin Cancer Res 9: 2933-2939.
12. DeGraffenried LA, Friedrichs WE, Fulcher L, Fernandes G, Silva JM, et al. (2003) Eicosapentaenoic acid restores tamoxifen sensitivity in breast cancer cells with high Akt activity. Ann Oncol 14: 1051-1056.
13. Frogne T, Jepsen JS, Larsen SS, Fog CK, Brockdorff BL, et al. (2005) Antiestrogen-resistant human breast cancer cells require activated protein kinase B/Akt for growth. Endocr Relat Cancer 12: 599-614.
14. Myatt SS, Lam EW (2007) The emerging roles of forkhead box (Fox) proteins in cancer. Nat Rev Cancer 7: 847-859.
15. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, et al. (1999) Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96: 857-868.
16. Hu MC, Lee DF, Xia W, Golfman LS, Ou-Yang F, et al. (2004) IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell 117: 225-237.
17. Jin GS, Kondo E, Miyake T, Shibata M, Takashima T, et al. (2004) Expression and intracellular localization of FKHRL1 in mammary gland neoplasms. Acta Med Okayama 58: 197-205.
18. Rosivatz E, Matthews JG, McDonald NQ, Mulet X, Ho KK, et al. (2006) A small molecule inhibitor for phosphatase and tensin homologue deleted on chromosome 10 (PTEN). ACS Chem Biol 1: 780-790.
19. Nordigarden A, Kraft M, Eliasson P, Labi V, Lam EW, et al. (2009) BH3-only protein Bim more critical than Puma in tyrosine kinase inhibitor-induced apoptosis of human leukemic cells and transduced hematopoietic progenitors carrying oncogenic FLT3. Blood 113: 2302-2311.
20. Brunner N, Zugmaier G, Bano M, Ennis BW, Clarke R, et al. (1989) Endocrine therapy of human breast cancer cells: the role of secreted polypeptide growth factors. Cancer Cells 1: 81-86.
21. Krol J, Francis RE, Albergaria A, Sunters A, Polychronis A, et al. (2007) The transcription factor FOXO3a is a crucial cellular target of gefitinib (Iressa) in breast cancer cells. Mol Cancer Ther 6: 3169-3179.
22. Sunters A, Fernandez de Mattos S, Stahl M, Brosens JJ, Zoumpoulidou G, et al. (2003) FoxO3a transcriptional regulation of Bim controls apoptosis in paclitaxeltreated breast cancer cell lines. J Biol Chem 278: 49795-49805.
23. Hui RC, Gomes AR, Constantinidou D, Costa JR, Karadedou CT, et al. (2008) The forkhead transcription factor FOXO3a increases phosphoinositide-3 kinase/Akt activity in drug-resistant leukemic cells through induction of PIK3CA expression. Mol Cell Biol 28: 5886-5898.
24. Hui RC, Francis RE, Guest SK, Costa JR, Gomes AR, et al. (2008) Doxorubicin activates FOXO3a to induce the expression of multidrug resistance gene ABCB1 (MDR1) in K562 leukemic cells. Mol Cancer Ther 7: 670-678.
25. Clark AS, West K, Streicher S, Dennis PA (2002) Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther 1: 707-717.
26. Fernandez de Mattos S, Villalonga P, Clardy J, Lam EW (2008) FOXO3a mediates the cytotoxic effects of cisplatin in colon cancer cells. Mol Cancer Ther 7: 3237-3246.
27. Sunters A, Madureira PA, Pomeranz KM, Aubert M, Brosens JJ, et al. (2006) Paclitaxel-induced nuclear translocation of FOXO3a in breast cancer cells is mediated by c-Jun NH2-terminal kinase and Akt. Cancer Res 66: 212-220.
28. McGovern UB, Francis RE, Peck B, Guest SK, Wang J, et al. (2009) Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer. Mol Cancer Ther 8: 582-591.
29. Kwok JM, Myatt SS, Marson CM, Coombes RC, Constantinidou D, et al. (2008) Thiostrepton selectively targets breast cancer cells through inhibition of forkhead box M1 expression. Mol Cancer Ther 7: 2022-2032.
30. Yang JY, Hung MC (2009) A new fork for clinical application: targeting forkhead transcription factors in cancer. Clin Cancer Res 15: 752-757.
31. Riggins RB, Bouton AH, Liu MC, Clarke R (2005) Antiestrogens, aromatase inhibitors, and apoptosis in breast cancer. Vitam Horm 71: 201-237.
32. Riggins RB, Zwart A, Nehra R, Clarke R (2005) The nuclear factor kappa B inhibitor parthenolide restores ICI 182,780 (Faslodex; fulvestrant)-induced apoptosis in antiestrogen-resistant breast cancer cells. Mol Cancer Ther 4: 33-41.
33. Storz P, Doppler H, Copland JA, Simpson KJ, Toker A (2009) FOXO3a promotes tumor cell invasion through the induction of matrix metalloproteinases. Mol Cell Biol 29: 4906-4917.